Aim: A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy. Methods: This comparative study was carried out in the Department of Obstetrics and Gynaecology, Netaji Subhas Medical College and Hospital, Bihta, Patna, Bihar, India. Women less than 10 days after delivery with hemoglobin between ≥6 g/dl and ≤11 gm/dl requiring iron supplementation were enrolled. Total 200 women were categorized into two groups 100 each. Detailed history and clinical examination were done. Diagnosis was confirmed by peripheral blood smear, CBC and serum ferritin. All women were dewormed. Results: Mean pre-treatment Hb was 8.1±0.77 and 8.11±0.61 in iron sucrose and ferric carboxy maltose group respectively. There was statistically significant rise (P <0.001) of Hb in FCM group 4.88 g/dl compared to iron sucrose group 3.82 g/dl. Mean rise of serum ferritin was 72.07±26.23 and 96.39±44.84 in iron sucrose and ferric carboxy maltose group. No serious adverse events were reported in either the FCM group or iron sucrose group. However, minor adverse effects like urticaria, injection site reactions, nausea hypotension occurred in 7 (7%) iron sucrose group and chest discomfort was noted in 2, nausea in 1, (3%) of FCM group. Conclusion: Properties like ultra-short duration of treatment, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of postpartum iron deficiency anemia.

Aim: A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy. Methods: This comparative study was carried out in the Department of Obstetrics and Gynaecology, Netaji Subhas Medical College and Hospital, Bihta, Patna, Bihar, India. Women less than 10 days after delivery with hemoglobin between ≥6 g/dl and ≤11 gm/dl requiring iron supplementation were enrolled. Total 200 women were categorized into two groups 100 each. Detailed history and clinical examination were done. Diagnosis was confirmed by peripheral blood smear, CBC and serum ferritin. All women were dewormed. Results: Mean pre-treatment Hb was 8.1±0.77 and 8.11±0.61 in iron sucrose and ferric carboxy maltose group respectively. There was statistically significant rise (P <0.001) of Hb in FCM group 4.88 g/dl compared to iron sucrose group 3.82 g/dl. Mean rise of serum ferritin was 72.07±26.23 and 96.39±44.84 in iron sucrose and ferric carboxy maltose group. No serious adverse events were reported in either the FCM group or iron sucrose group. However, minor adverse effects like urticaria, injection site reactions, nausea hypotension occurred in 7 (7%) iron sucrose group and chest discomfort was noted in 2, nausea in 1, (3%) of FCM group. Conclusion: Properties like ultra-short duration of treatment, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of postpartum iron deficiency anemia.